Kuder Margaret M, Lang David M, Patadia Deepa D
Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, Cleveland OH
Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, Cleveland OH.
Cleve Clin J Med. 2021 Mar 1. doi: 10.3949/ccjm.88a.ccc075.
Recent reports of allergic reactions to the Pfizer-BioNTech and the Moderna COVID-19 vaccines have resulted in questions about how and to whom they can be safely administered. Although anaphylaxis was not observed in clinical trials for either vaccine, there have been 21 reported possible cases of anaphylaxis associated with the Pfizer vaccine (11.1 cases per million doses administered) and 10 possible cases associated with the Moderna vaccine (2.5 anaphylaxis cases per million doses administered). The etiology of anaphylaxis in these cases is not fully understood and is an area of active research. The overall incidence of anaphylaxis to COVID-19 mRNA vaccines is very low. By following recommendations from the US Centers for Disease Control and Prevention, an overwhelming majority of the US population can be safely immunized.
最近有关辉瑞-生物科技公司和莫德纳新冠疫苗过敏反应的报道引发了关于如何安全接种以及哪些人可以安全接种的问题。尽管两种疫苗的临床试验中均未观察到过敏反应，但已报告有21例可能与辉瑞疫苗相关的过敏反应病例（每接种100万剂有11.1例），以及10例可能与莫德纳疫苗相关的过敏反应病例（每接种100万剂有2.5例过敏反应）。这些病例中过敏反应的病因尚未完全明确，是一个正在积极研究的领域。新冠mRNA疫苗过敏反应的总体发生率非常低。遵循美国疾病控制与预防中心的建议，绝大多数美国民众都可以安全接种疫苗。
